Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.38 |
| ▸ | MARS1 | P56192 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43448 | 0.84 | ALDH1A1 (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18769324 | 0.84 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5281973 | 0.84 | TAAR1 (0.55) | MAOBTAAR1CYP19A1 | |
| Hydrochloric Acid SCHEMBL2479666 | 0.82 | ALDH1A1 (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8223455 | 0.81 | PTGS2 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL586588 | 0.81 | MARS1 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3933664 | 0.79 | MARS1 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL586319 | 0.79 | DAO (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL603252 | 0.79 | ALDH1A1 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3939805 | 0.79 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648762-A2 | PPARG MODULATORS | University of Florida Research Foundation, Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3836919-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | Recreo Pharmaceuticals Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2520566-A1 | New Pharmaceutical Compounds | Orion Corporation (FI) | 2012-11-07 | — | — | EP | disclosed |
| US-7799947-B2 | In vivo imaging compounds | HAMMERSMITH IMANET LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799947-B2 | In vivo imaging compounds | HAMMERSMITH IMANET LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799947-B2 | In vivo imaging compounds | HAMMERSMITH IMANET LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GE HEALTHCARE LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| EP-1954259-A2 | AMIDINE DERIVATIVES FOR IN VIVO IMAGING | Hammersmith Imanet, Ltd (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007063286-A2 | AMIDINE DERIVATIVES FOR IN VIVO IMAGING | HAMMERSMITH IMANET LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063286-A2 | AMIDINE DERIVATIVES FOR IN VIVO IMAGING | HAMMERSMITH IMANET LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | GRIN2D 2248/4885GRIN3B 1460/4885GRIN1 1101/4885 |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 | GRIN2D 1280/4885GRIN3B 636/4885GRIN1 592/4885 |
| US-20090155168-A1 | IN VIVO IMAGING COMPOUNDS | GRIN1, GRIN2B, GRIN3B | GRIN2D 7/4885GRIN3B 3/4885GRIN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.